http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories
-
AMGEN TO PRESENT AT GOLDMAN SACHS 46TH ANNUAL GLOBAL HEALTHCARE CONFERENCE
-
AMGEN TO PRESENT AT JEFFERIES GLOBAL HEALTHCARE CONFERENCE
-
AMGEN TO PRESENT AT THE 2025 RBC CAPITAL MARKETS GLOBAL HEALTHCARE CONFERENCE
-
AMGEN TO PRESENT AT THE BANK OF AMERICA MERRILL LYNCH GLOBAL HEALTHCARE CONFERENCE
-
AMGEN REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS
-
AMGEN ANNOUNCES WEBCAST OF 2025 FIRST QUARTER FINANCIAL RESULTS
-
AMGEN TO PRESENT AT THE 45TH ANNUAL TD COWEN HEALTH CARE CONFERENCE
-
AMGEN TO PRESENT AT CITI'S 2025 VIRTUAL ONCOLOGY LEADERSHIP SUMMIT
-
Asher Bio Announces Clinical Trial Collaboration and Supply Agreement on Etakafusp Alfa (AB248) in Combination with Bispecific T-cell Engager in Patients with Small Cell Lung Cancer
-
AMGEN TO PRESENT AT CITI'S 2024 GLOBAL HEALTHCARE CONFERENCE
-
AMGEN TO PRESENT AT THE 7th ANNUAL EVERCORE HEALTHCONx CONFERENCE
-
AMGEN TO HOST WEBCAST TO DISCUSS MARITIDE PHASE 2 RESULTS AND PROGRESS ON DEVELOPMENT PROGRAM
-
Amgen (AMGN) Appoints Howard Chang as SVP of Research
-
AMGEN ANNOUNCES SENIOR EXECUTIVE RESEARCH APPOINTMENT
-
10 policies if Trump wins and stock implications: Jefferies
-
Biotechs Race to Develop New Treatments as Global Pancreatic Cancer Market Size Expected to Reach $7.5 Billion by 2033
-
Ligand Reports First Quarter 2024 Financial Results
-
Arrowhead Pharmaceuticals Earns $50 Million Milestone from Royalty Pharma
-
AMGEN TO PRESENT TEZSPIRE® PHASE 2A COPD DATA AT ATS 2024
-
AMGEN PRESENTS NEW RESEARCH ON OTEZLA® (APREMILAST) AT AAD 2024
-
AMGEN ANNOUNCES 2024 SECOND QUARTER DIVIDEND
-
AMGEN TO PRESENT AT THE 44TH ANNUAL TD COWEN HEALTH CARE CONFERENCE
-
AMGEN OPENS STATE-OF-THE-ART BIOMANUFACTURING SITE IN CENTRAL OHIO
-
AMGEN TO HOST CONFERENCE CALL ON RARE DISEASE
-
AMGEN TO PRESENT AT THE 34TH ANNUAL OPPENHEIMER HEALTHCARE LIFE SCIENCES CONFERENCE
-
AMGEN REPORTS FOURTH QUARTER AND FULL YEAR 2023 FINANCIAL RESULTS
-
AMGEN ANNOUNCES WEBCAST OF 2023 FOURTH QUARTER AND FULL YEAR FINANCIAL RESULTS
-
Global Oncology Cancer Drugs Market Revenue Projected To Surpass $289 Billion By 2030
-
Generate:Biomedicines Fortifies Leadership in Generative AI with Advancing Clinical Pipeline and Expanded Amgen Collaboration, Overviewed at the 42nd Annual J.P. Morgan Healthcare Conference
-
AMGEN TO PRESENT AT THE 42ND ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE
-
Amgen (AMGN) Receives CRL for LUMAKRAS NDA
-
AMGEN PROVIDES REGULATORY UPDATE ON STATUS OF LUMAKRAS® (SOTORASIB)
-
Amgen (AMGN) Announces Executive Appointments To Accelerate Innovation
-
AMGEN ANNOUNCES EXECUTIVE APPOINTMENTS TO ACCELERATE INNOVATION
-
AMGEN TO SPONSOR THE IRISH OPEN
-
Amgen (AMGN) Announces FDA Grants Priority Review to Tarlatamab Application for Advanced Small Cell Lung Cancer
-
FDA Grants Priority Review to Amgen's Tarlatamab Application for Advanced Small Cell Lung Cancer
-
AMGEN ANNOUNCES 2024 FIRST QUARTER DIVIDEND INCREASE TO $2.25 PER SHARE
-
AMGEN HIGHLIGHTS HEMATOLOGY PORTFOLIO AT ASH 2023
-
AMGEN TO PRESENT AT THE EVERCORE ISI HEALTHCONX CONFERENCE
-
AMGEN PRESENTS NEW CARDIOVASCULAR RESEARCH AT AHA 2023
-
Ligand Reports Third Quarter 2023 Financial Results
-
AMGEN PRESENTS NEW RESEARCH IN EARLY PSORIATIC ARTHRITIS AT ACR 2023
-
AMGEN PRESENTS NEW DATA FROM PHASE 2 TRIAL OF DAZODALIBEP IN SJÖGREN'S SYNDROME AT ACR 2023
-
AMGEN PRESENTS NEW DATA THAT SHOW BLOOD PRESSURE DECREASES FOR ADULTS TREATED WITH KRYSTEXXA® (PEGLOTICASE)
-
AMGEN TO PRESENT DATA AT ACR 2023 ACROSS EXPANDED RHEUMATOLOGY PIPELINE AND PORTFOLIO
-
AMGEN REPORTS THIRD QUARTER FINANCIAL RESULTS
-
AMGEN ANNOUNCES WEBCAST OF 2023 THIRD QUARTER FINANCIAL RESULTS
-
AMGEN ANNOUNCES 2023 FOURTH QUARTER DIVIDEND
-
AMGEN PRESENTS NEW LUMAKRAS® (SOTORASIB) PLUS VECTIBIX® (PANITUMUMAB) DATA IN PATIENTS WITH KRAS G12C-MUTATED METASTATIC COLORECTAL CANCER
